Efficacy and Safety of TANIT Platform Combining Dampened Bioactive Current and Functional Dermal Stimulation for the Treatment of Adipose Tissue in Patients with Stage I or II Lipedema

The study's main objective was to assess the efficacy and safety of TANIT, a platform combining functional dermal stimulation with damped bioactive current and mechanical stimulation to reduce adipose tissue (AT) in patients with stage I (SI) or II (SII) lipedema. A single-center, before-after clinical trial without a control group was conducted on adult women diagnosed with SI or SII lipedema. Patients underwent a treatment protocol for 5 weeks, with weekly sessions. Blood tests, AT thickness, pain threshold, and anthropometric measurements were assessed at baseline and the end of the study, and a satisfaction survey was conducted after treatment. Twenty-three women were enrolled with a mean age of 44.91 (standard deviation 11.58) and a median of 46.00 (Q25 = 36.50, Q75 = 51.50). Seven (30.4%) patients had SI lipedema and 16 (69.6%) had SII. The pain threshold increased in 78.3% of patients at the knee level and 80.0% at the ankle level. Lower limb volume decreased in 78.3% of patients. AT thickness decreased in all treated areas, with a mean decrease of 26.1% at the ankles, 14.5% at the knees, and 17.4% at the trochanter level. Patients reported high satisfaction with the results obtained after the treatment sessions, and no unexpected adverse effects were found. The TANIT platform provided an effective and safe conservative treatment option for patients with S and SII lipedema, reducing leg volume, AT thickness, and pain. However, additional randomized clinical trials and standardized assessment tools would be necessary.